Keith Ellison said he's reached a deal with Danish pharmaceutical company Novo Nordisk to keep the cost of insulin at $35 a ...

Rosen Law Firm, a global investor rights law firm, reminds purchasers of stock of BioAge Labs, Inc. (NASDAQ:BIOA) pursuant and/or traceable to BioAge's registration statement for the initial public ...

For five years, insulin manufacturer Novo Nordisk agrees to cap out-of-pocket cost of its insulin treatments at $35 per month, and provide free insulin to the neediest Minnesotans.

Eli Lilly earnings topped Q4 views with 2025 guidance above consensus, even though Zepbound and Mounjaro slightly missed. Eli Lilly stock rose.

Over the past six months, Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, it is still a bit surprising, since the ...

Eli Lilly's sales growth is coming short of expectations, which is a problem considering its valuation. The company does have a vast lineup and a deep pipeline that go beyond diabetes and obesity.

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

(MENAFN- GlobeNewsWire - Nasdaq) NEW YORK, Feb. 02, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit ... with Eli Lilly and Company ...

NEW YORK, Feb. 02, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been ... was collaborating with Eli Lilly and Company (“Lilly ...